392 related articles for article (PubMed ID: 36429065)
1. O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.
Zhou Y; Li Z; Xu M; Zhang D; Ling J; Yu P; Shen Y
Cells; 2022 Nov; 11(22):. PubMed ID: 36429065
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function.
Gonzalez-Rellan MJ; Parracho T; Heras V; Rodriguez A; Fondevila MF; Novoa E; Lima N; Varela-Rey M; Senra A; Chantada-Vazquez MDP; Ameneiro C; Bernardo G; Fernandez-Ramos D; Lopitz-Otsoa F; Bilbao J; Guallar D; Fidalgo M; Bravo S; Dieguez C; Martinez-Chantar ML; Millet O; Mato JM; Schwaninger M; Prevot V; Crespo J; Frühbeck G; Iruzubieta P; Nogueiras R
Mol Metab; 2023 Sep; 75():101776. PubMed ID: 37453647
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36.
Zhu H; Zhao T; Zhao S; Yang S; Jiang K; Li S; Kang Y; Yang Z; Shen J; Shen S; Tao H; Xuan J; Yang M; Xu B; Wang F; Jiang M
Metabolism; 2024 Jul; 156():155914. PubMed ID: 38642829
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation.
Zhu Q; Zhou L; Yang Z; Lai M; Xie H; Wu L; Xing C; Zhang F; Zheng S
Med Oncol; 2012 Jun; 29(2):985-93. PubMed ID: 21461968
[TBL] [Abstract][Full Text] [Related]
5. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
6. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
9. Biological Functions and Potential Therapeutic Significance of O-GlcNAcylation in Hepatic Cellular Stress and Liver Diseases.
Mao Z; Mu J; Gao Z; Huang S; Chen L
Cells; 2024 May; 13(10):. PubMed ID: 38786029
[TBL] [Abstract][Full Text] [Related]
10. Curcumin Ameliorates Nonalcoholic Fatty Liver Disease through Inhibition of
Lee DE; Lee SJ; Kim SJ; Lee HS; Kwon OS
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31717261
[TBL] [Abstract][Full Text] [Related]
11. Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD.
Xie Z; Xie T; Liu J; Zhang Q; Xiao X
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768465
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease.
Teng T; Qiu S; Zhao Y; Zhao S; Sun D; Hou L; Li Y; Zhou K; Yu X; Yang C; Li Y
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887189
[TBL] [Abstract][Full Text] [Related]
13. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
Branković M; Jovanović I; Dukić M; Radonjić T; Oprić S; Klašnja S; Zdravković M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563534
[TBL] [Abstract][Full Text] [Related]
14. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
Xu W; Zhang X; Wu JL; Fu L; Liu K; Liu D; Chen GG; Lai PB; Wong N; Yu J
J Hepatol; 2017 Aug; 67(2):310-320. PubMed ID: 28347804
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
16. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
Huang W; Zhang XX
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
[TBL] [Abstract][Full Text] [Related]
17. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
[TBL] [Abstract][Full Text] [Related]
18. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
20. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.
Fujii H; Kawada N; Japan Study Group Of Nafld Jsg-Nafld
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
